AptarGroup Inc
ATR: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$453.00 | Yhkpkvz | Wmsdtmzc |
Aptar's Pharma Business Drives Growth; We Maintain Our $132 Fair Value Estimate, Shares Undervalued
Narrow-moat Aptar delivered solid fourth-quarter and full-year results driven primarily by its Pharma business and volume growth in beauty and home. Full-year 2022 results are in line with our assumptions, and we are maintaining our $132 fair value estimate. Shares appear undervalued.